Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.70 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.37 |
| ▸ | ACE | P12821 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4278865 | 1.00 | ATM (0.70) | ATMMMEPIK3CDACEALDH1A1 | |
| SCHEMBL2744860 | 1.00 | ATM (0.70) | ATMMMEPIK3CDACEALDH1A1 | |
| SCHEMBL30729565 | 1.00 | ATM (0.70) | ATMMMEPIK3CDACEALDH1A1 | |
| SCHEMBL1249538 | 1.00 | ATM (0.70) | ATMMMEPIK3CDACEALDH1A1 | |
| SCHEMBL3524882 | 1.00 | ATM (0.70) | ATMMMEPIK3CDACEALDH1A1 | |
| SCHEMBL19859070 | 1.00 | ATM (0.70) | ATMMMEPIK3CDACEALDH1A1 | |
| SCHEMBL1249542 | 1.00 | ATM (0.70) | ATMMMEPIK3CDACEALDH1A1 | |
| SCHEMBL4041451 | 1.00 | ATM (0.70) | ATMMMEPIK3CDACEALDH1A1 | |
| Oxaceprol SCHEMBL25978 | 0.83 | ATM (1.00) | ATMMMEPIK3CDACEALDH1A1 | |
| Oxaceprol SCHEMBL25977 | 0.83 | ATM (1.00) | ATMMMEPIK3CDACEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688788-A1 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | Pfizer Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4551566-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Les Laboratoires Servier (FR) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024220532-A1 | PYRROLIDINE KRAS INHIBITORS | INCYTE CORPORATION (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024209339-A1 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| EP-4305038-A1 | KRAS G12D INHIBITORS | Bristol-Myers Squibb Company (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2024008941-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2024-01-11 | — | — | WO | disclosed |
| CN-116685576-A | Cysteine protease inhibitors and methods of use thereof | 美商帕迪斯生物科学公司 | 2023-09-01 | — | — | CN | disclosed |
| WO-2022192794-A1 | KRAS G12D INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-15 | — | — | WO | disclosed |
| EP-3969442-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | Kinnate Biopharma Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| WO-2020120539-A1 | NEW PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-06-18 | — | — | WO | disclosed |
| EP-2279737-B1 | Heterocyclic compounds that are active as beta lactamase inhibitors | NOVEXEL (FR) | 2012-10-31 | — | — | EP | disclosed |
| EP-2279737-A1 | Heterocyclic compounds that are active as beta lactamase inhibitors | NOVEXEL (FR) | 2011-02-02 | — | — | EP | disclosed |
| EP-1480644-B1 | NOVEL HETEROCYCLIC COMPOUNDS WHICH ARE ACTIVE AS INHIBITORS OF BETA+LACTAMASES | NOVEXEL (FR) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009108507-A1 | THERAPEUTIC COMPOUNDS | MERCK & CO., INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| EP-1879607-A2 | HCV NS3 PROTEASE INHIBITORS | Merck & Co., Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006119061-A2 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2006-11-09 | — | — | WO | disclosed |
| US-7030141-B2 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2006-04-18 | — | — | US | disclosed |
| EP-1307457-B1 | AZABICYCLIC COMPOUNDS, PREPARATION THEREOF AND USE AS MEDICINES, IN PARTICULAR AS ANTIBACTERIAL AGENTS | AVENTIS PHARMA SA (FR) | 2004-04-07 | — | — | EP | disclosed |
| US-5928933-A | SEPARATING RACEMIC MIXTURE BY ENANTIOSELECTIVELY HYDROLYZING THE ESTER OF THE L-ISOMER; CHEMICAL INTERMEDIATE FOR 4-HYDROXYPROLINE | E. I. DU PONT DE NEMOURS & COMPANY (US) | 1999-07-27 | — | — | US | disclosed |
| EP-0696593-A2 | Inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-02-14 | — | — | EP | disclosed |